A systematic review of oxymorphone in the management of chronic pain

Fadia Mayyas, Peter Fayers, Stein Kaasa, Ola Dale

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Opioids are recommended for control of moderate-to-severe, chronic, malignant, and nonmalignant pain. A controlled-release formulation of the opioid oxymorphone has recently been launched. The aim of this review was to assess the effectiveness of oxymorphone as an analgesic in chronic pain. A systematic search for published studies of oral oxymorphone in the management of chronic pain was conducted. The studies were evaluated for their internal validity according to standard criteria. They were also evaluated for their external validity and research ethic aspects. A meta-analysis was performed to examine the effect of oxymorphone compared with placebo. Nine studies were evaluated; three were excluded because of low quality. Six controlled studies (duration 2-12 weeks) included a total of 1489 subjects suffering from chronic low back pain, chronic pain from osteoarthritis, and chronic cancer pain. Three of the studies were of high quality and three of medium quality. External validity was assessed to be high, medium, and low (in one, three, and two studies, respectively). The meta-analysis suggests that daily doses of 40-100mg are superior to placebo; however, the estimate (reduction of pain intensity compared with placebo) of the treatment effect is imprecise (95% confidence interval -17.08, -8.69). Limited evidence suggests that oxymorphone is effective for pain control in patients with cancer. No significant differences between oxymorphone and oxycodone at equipotent doses were found. In conclusion, oxymorphone is superior to placebo. There is no evidence that the efficacy of oxymorphone differs from other opioids.
Original languageEnglish
Pages (from-to)296-308
Number of pages13
JournalJournal of Pain and Symptom Management
Volume39
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Oxymorphone
Chronic Pain
Opioid Analgesics
Placebos
Pain
Meta-Analysis
Oxycodone
Research Ethics
Placebo Effect
Low Back Pain
Osteoarthritis
Analgesics
Confidence Intervals

Keywords

  • oxymorphone
  • extended release
  • opioids
  • chronic pain
  • cancer
  • osteoarthritis
  • low back pain
  • systematic review

Cite this

A systematic review of oxymorphone in the management of chronic pain. / Mayyas, Fadia; Fayers, Peter; Kaasa, Stein; Dale, Ola.

In: Journal of Pain and Symptom Management, Vol. 39, No. 2, 02.2010, p. 296-308.

Research output: Contribution to journalArticle

Mayyas, Fadia ; Fayers, Peter ; Kaasa, Stein ; Dale, Ola. / A systematic review of oxymorphone in the management of chronic pain. In: Journal of Pain and Symptom Management. 2010 ; Vol. 39, No. 2. pp. 296-308.
@article{45d9d36c67e9426ba8cc2f52fa3e7c3b,
title = "A systematic review of oxymorphone in the management of chronic pain",
abstract = "Opioids are recommended for control of moderate-to-severe, chronic, malignant, and nonmalignant pain. A controlled-release formulation of the opioid oxymorphone has recently been launched. The aim of this review was to assess the effectiveness of oxymorphone as an analgesic in chronic pain. A systematic search for published studies of oral oxymorphone in the management of chronic pain was conducted. The studies were evaluated for their internal validity according to standard criteria. They were also evaluated for their external validity and research ethic aspects. A meta-analysis was performed to examine the effect of oxymorphone compared with placebo. Nine studies were evaluated; three were excluded because of low quality. Six controlled studies (duration 2-12 weeks) included a total of 1489 subjects suffering from chronic low back pain, chronic pain from osteoarthritis, and chronic cancer pain. Three of the studies were of high quality and three of medium quality. External validity was assessed to be high, medium, and low (in one, three, and two studies, respectively). The meta-analysis suggests that daily doses of 40-100mg are superior to placebo; however, the estimate (reduction of pain intensity compared with placebo) of the treatment effect is imprecise (95{\%} confidence interval -17.08, -8.69). Limited evidence suggests that oxymorphone is effective for pain control in patients with cancer. No significant differences between oxymorphone and oxycodone at equipotent doses were found. In conclusion, oxymorphone is superior to placebo. There is no evidence that the efficacy of oxymorphone differs from other opioids.",
keywords = "oxymorphone, extended release, opioids, chronic pain, cancer, osteoarthritis, low back pain, systematic review",
author = "Fadia Mayyas and Peter Fayers and Stein Kaasa and Ola Dale",
note = "Copyright 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.",
year = "2010",
month = "2",
doi = "10.1016/j.jpainsymman.2009.07.010",
language = "English",
volume = "39",
pages = "296--308",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - A systematic review of oxymorphone in the management of chronic pain

AU - Mayyas, Fadia

AU - Fayers, Peter

AU - Kaasa, Stein

AU - Dale, Ola

N1 - Copyright 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

PY - 2010/2

Y1 - 2010/2

N2 - Opioids are recommended for control of moderate-to-severe, chronic, malignant, and nonmalignant pain. A controlled-release formulation of the opioid oxymorphone has recently been launched. The aim of this review was to assess the effectiveness of oxymorphone as an analgesic in chronic pain. A systematic search for published studies of oral oxymorphone in the management of chronic pain was conducted. The studies were evaluated for their internal validity according to standard criteria. They were also evaluated for their external validity and research ethic aspects. A meta-analysis was performed to examine the effect of oxymorphone compared with placebo. Nine studies were evaluated; three were excluded because of low quality. Six controlled studies (duration 2-12 weeks) included a total of 1489 subjects suffering from chronic low back pain, chronic pain from osteoarthritis, and chronic cancer pain. Three of the studies were of high quality and three of medium quality. External validity was assessed to be high, medium, and low (in one, three, and two studies, respectively). The meta-analysis suggests that daily doses of 40-100mg are superior to placebo; however, the estimate (reduction of pain intensity compared with placebo) of the treatment effect is imprecise (95% confidence interval -17.08, -8.69). Limited evidence suggests that oxymorphone is effective for pain control in patients with cancer. No significant differences between oxymorphone and oxycodone at equipotent doses were found. In conclusion, oxymorphone is superior to placebo. There is no evidence that the efficacy of oxymorphone differs from other opioids.

AB - Opioids are recommended for control of moderate-to-severe, chronic, malignant, and nonmalignant pain. A controlled-release formulation of the opioid oxymorphone has recently been launched. The aim of this review was to assess the effectiveness of oxymorphone as an analgesic in chronic pain. A systematic search for published studies of oral oxymorphone in the management of chronic pain was conducted. The studies were evaluated for their internal validity according to standard criteria. They were also evaluated for their external validity and research ethic aspects. A meta-analysis was performed to examine the effect of oxymorphone compared with placebo. Nine studies were evaluated; three were excluded because of low quality. Six controlled studies (duration 2-12 weeks) included a total of 1489 subjects suffering from chronic low back pain, chronic pain from osteoarthritis, and chronic cancer pain. Three of the studies were of high quality and three of medium quality. External validity was assessed to be high, medium, and low (in one, three, and two studies, respectively). The meta-analysis suggests that daily doses of 40-100mg are superior to placebo; however, the estimate (reduction of pain intensity compared with placebo) of the treatment effect is imprecise (95% confidence interval -17.08, -8.69). Limited evidence suggests that oxymorphone is effective for pain control in patients with cancer. No significant differences between oxymorphone and oxycodone at equipotent doses were found. In conclusion, oxymorphone is superior to placebo. There is no evidence that the efficacy of oxymorphone differs from other opioids.

KW - oxymorphone

KW - extended release

KW - opioids

KW - chronic pain

KW - cancer

KW - osteoarthritis

KW - low back pain

KW - systematic review

U2 - 10.1016/j.jpainsymman.2009.07.010

DO - 10.1016/j.jpainsymman.2009.07.010

M3 - Article

VL - 39

SP - 296

EP - 308

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 2

ER -